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Abstract: Metastasis to the brain is a feared complication of systemic cancer, associated 
with significant morbidity and poor prognosis. A better understanding of the tumor 
metabolism might help us meet the challenges in controlling brain metastases. The study 
aims to characterize the metabolic profile of brain metastases of different origin using high 
resolution magic angle spinning (HR-MAS) magnetic resonance spectroscopy (MRS) to 
correlate the metabolic profiles to clinical and pathological information. Biopsy samples of 
human brain metastases (n = 49) were investigated. A significant correlation between lipid 
signals and necrosis in brain metastases was observed (p < 0.01), irrespective of their 
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primary origin. The principal component analysis (PCA) showed that brain metastases 
from malignant melanomas cluster together, while lung carcinomas were metabolically 
heterogeneous and overlap with other subtypes. Metastatic melanomas have higher 
amounts of glycerophosphocholine than other brain metastases. A significant correlation 
between microscopically visible lipid droplets estimated by Nile Red staining and MR visible 
lipid signals was observed in metastatic lung carcinomas (p = 0.01), indicating that the proton 
MR visible lipid signals arise from cytoplasmic lipid droplets. MRS-based metabolomic 
profiling is a useful tool for exploring the metabolic profiles of metastatic brain tumors. 
Keywords: magnetic resonance; spectroscopy; high-resolution; metabolite; ex vivo; 
cancer; carcinomas; metastasis 
 
1. Introduction 
Metastases are the most common cancers of the central nervous system and a feared complication 
of systemic cancer with significant morbidity and a poor prognosis. The true incidence is unknown and 
probably underestimated [1,2]. Brain metastases from lung, melanoma, breast, kidney and colon 
carcinomas are most frequently observed [1]. Treatment modalities include chemotherapy, stereotactic 
radiosurgery, whole brain radiotherapy and surgery. The treatment offered depends on the origin of the 
metastases, clinical condition of the patient, tumor size and also number, depth and mass effect of 
lesions [3,4]. Age, Karnofsky performance status (KPS), number of intracranial metastases and the 
presence of extracranial metastases are established prognostic factors [5,6]. A recent study of patients 
with brain metastases treated with radiotherapy showed that more than 30% died within three  
months [7]. Studies of a similar patient cohort, stratified by graded prognostic assessment and treated 
by open surgery, showed a three-months’ mortality rate of 17% [8,9]. Hence, there is a substantial 
need for improved methods to identify prognostic markers that can help to risk-stratify these patients.  
Magnetic resonance (MR) metabolomics of intact tissue is being increasingly recognized as a 
promising tool within oncology. High resolution magic angle spinning (HR-MAS) magnetic resonance 
spectroscopy (MRS) is a novel analytical method that provides detailed biochemical information of 
intact tissue samples. Even though experimental conditions might cause minimal structural damage, 
post HR-MAS analyses enable reasonable comparisons of metabolic information with histopathological 
data [10] or molecular methods, such as gene expression [11]. Several studies suggest that metabolic 
profiling provides valuable information in cancer diagnostics [12,13], characterization and treatment 
monitoring [14,15]. Brain metastases of different origin have previously been described by HR-MAS 
to consist of more than 30 metabolites, dominated by lipid signals in many of the investigated  
samples [16]. The metabolic profile was found to reflect the origin of the metastases and to correlate to 
patient prognosis [16]. Metabolic profiling by HR-MAS MRS might contribute to improve our 
understanding of the biology of the different brain metastasis. 
The objectives of this study were to characterize the metabolic profile of brain metastases of 
different origin using HR-MAS MRS, to correlate the metabolic information to clinical and 
histopathological parameters and to further explore the source of MR visible lipids. 
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2. Results and Discussion 
2.1. Histopathology 
The routine histopathology assigned the samples of brain metastases to originate from malignant 
melanomas (n = 6), various carcinomas (breast (n = 6), colorectal (n = 12), lung (n = 20), uterine 
cervical (n = 2), esophageal (n = 1), renal (n = 1)) and one of unknown origin (n = 1). In addition to the 
one of unknown origin, the metastases originating from uterine cervical, esophageal and renal 
carcinomas were excluded from the study due to the low number of samples (n < 3). The 
characteristics of the remaining patient cohort (n = 44) and samples are presented in Table 1. 
Table 1. Patient and sample characteristics (n = 44). 
  Origin of Carcinomas 
Variables Total cohort Lung Colorectal Breast Melanoma
Numbers 44 20 12 6 6 
Female/Male 20/24 9/11 5/7 6/0 0/6 
Median Age at Surgery (Range) 63 (37–80) 69 (38–80) 63 (43–81) 53 (45–66) 65 (53–76)
KPS%: 
90–100 
70–80 
<70 
 
13 
25 
6 
 
5 
12 
3 
 
2 
8 
2 
 
3 
2 
1 
 
3 
3 
0 
Five Month Postoperative Survival 28 12 9 4 3 
KPS = Karnofsky Performance Status (0–100). 
Post HR-MAS histological assessment was performed in all samples (n = 44) and concurred with 
the initial histopathological diagnoses. Five samples, where their post HR-MAS histology 
predominantly composed of brain tissue or fibrotic tissue, were excluded from further statistical 
analyses. The relative content of tumor tissue, necrosis and fibrosis in the remaining cohort (n = 39) is 
shown in Table 2. The non-destructive nature of HR-MAS spectroscopy of tissue allowed precise 
characterization of the same tissue samples by histopathological post-processing, and further 
investigations, such as gene expression studies, can also be performed [12,17].  
Table 2. Origin and mean percentages (± SD) of tumor, necrotic and fibrotic tissue of the 
brain metastases samples (n = 39), described by HES-staining after high resolution magic 
angle spinning (HR-MAS) analysis. 
Origin Carcinomas of the Brain Metastases: Tumor (%) Necrosis (%) Fibrosis (%)
Lung (n = 17) 49 ± 31 36 ± 34 12 ± 17 
Colorectal (n = 11) 35 ± 24 48 ± 32 14 ± 23 
Breast (n = 5) 25 ± 5 34 ± 30 35 ± 27 
Malignant Melanoma (n = 6) 83 ± 15 8 ± 8 10 ± 15 
n = number, HES = hematoxylin, eosin and saffron staining. 
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2.2. MR Metabolomics 
The type of information obtained from HR-MAS strongly depends on the type of MR experiment. 
In this study, pre-saturated, single-pulse (zgpr) experiments were performed to obtain water suppressed 
spectra showing various metabolites (Figure 1a). To remove the broad signals from lipids and 
macromolecules, subsequent spin-echo (cpmgpr) experiments were performed (Figure 1b). Separate 
multivariate analyses were done on the spectral data obtained from both of these experiments.  
Figure 1. Representative proton HR-MAS spectra from a patient with brain metastasis 
from lung carcinoma obtained as (a) pre-saturated, single-pulse spectrum and (b) spin-echo 
spectrum, showing assignment of various metabolites. The enlarged ppm region  
3.6–3.0 ppm shows more details of glycine (Gly), myo-inositol (myo-In), taurine (Tau),  
scyllo-inositol (scy-In), glycerophosphocholine (GPC), phosphocholine (PCho),  
choline (Cho) and creatine (Cr). 
 
2.2.1. Brain Metastases and Lipid Metabolites 
In this study, we observed high lipid levels in the spectra from many of the brain metastasis 
samples. MR-visible lipids are triglycerides and cholesterol esters that accumulate in lipid droplets 
(a) 
(b) 
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(LD) arising in response to unfavorable conditions in the tumor microenvironment [18–21]. In vivo 
and ex vivo MRS studies of brain tumors have demonstrated that gliomas and brain metastases are 
characterized by dominating lipid signals [21–23]. A correlation between these lipid signals and 
amount of necrosis has been demonstrated in ex vivo studies of gliomas [24–26]. High levels of  
MR-visible lipids in metastases may therefore also be related to the amount of necrosis [27]. However, 
cellular response to stressful stimuli from the tumor microenvironment can result in accumulation of 
neutral lipids in cytoplasm. It has been shown that MR-visible lipid signals in non-necrotic brain tumor 
biopsies are mobile lipid droplets of cytoplasmic origin [21,25]. Further, apoptosis and hypoxic cells 
have been reported to contribute to elevated spectral lipid signals [28].  
In our study, we found a significant correlation (p < 0.01, Spearman two-tailed) between spectral 
lipid signals and the percentage of necrotic tissue in the brain metastases. To explore the variation in 
the spectral data, principal component analyses (PCA) were performed. Figure 2a shows the PCA 
score plot of the first (PC-1) versus the third (PC-3) principle component from the analyses of the 
single-pulse spectra. The necrotic fraction in the samples increases along the PC-1 axis of the score 
plot. The corresponding loading profile (Figure 2b) shows that high lipid levels are associated with 
necrosis. Partial least square (PLS) regression of the same spectra showed a correlation between the 
metabolic profile and necrotic fraction (r2 = 0.31), proved significant by permutation testing (n = 10,000,  
p = 0.047). This is in accordance with several previous studies of brain tumors, where MR-visible lipid 
signals correlated with necrosis [22,25,27,29,30]. The sample scattering along the PC-3 direction in 
Figure 2a is mainly due to differences in phosphocholine (PCho). Clustering according to the origin of 
the metastases is not so distinct; however, the brain metastases from malignant melanoma tend to 
cluster as a group of low lipid containing samples with low values of both PC-1 and PC-3 (Figure 2). 
The metastases from breast carcinomas appear with low PC-3, but both low and high PC-1, while both 
metastases from lung and colorectal carcinomas appear to be very heterogeneous as they disperse over 
the scatter plot. A recent HR-MAS study showed that histological subtypes of patients with primary 
lung carcinomas can be identified by PLS-analyses of MR spectra [31]. Most of the samples of brain 
metastases from lung carcinomas in our study were adenocarcinomas and, hence, the cohort is too 
small for a meaningful subtype analysis. The PCA demonstrate the large impact of lipids on the 
distribution of the samples. However, metastatic tumors with a higher degree of estimated necrosis by 
histopathology cluster together irrespective of their primary origin. 
Differences in lengths and numbers of double bonds in fatty acyl chains generate MR signals at 
different chemical shifts (ppm). The broad signal at 0.9 ppm is the joint signal for the terminal methyl 
group (–CH3), found in all fatty acyl chains. When the spectral lipids at the ppm values 1.3, 1.55, 2.05, 
2.25 and 2.82 were scaled relative to the signal at 0.9 ppm and compared to the necrotic fraction in the 
samples, only the 1.3 ppm signal correlated significantly with necrosis. Since the signal at 1.3 ppm  
((–CH2)n) indicates the degree of saturation in fatty acids, this indicates an abundance of saturated fatty 
acid in necrosis.  
To further explore and compare any prognostic value of the metabolic information, the histological 
and clinical parameters (tumor tissue fractions, age and survival) were related to the metabolic profiles 
by PLS. No significant correlations between metabolic profiles and patient age or survival at three or 
five months after surgery was observed, and previous intriguing results were thus not confirmed [16]. 
This is probably due to the large heterogeneity of this patient cohort regarding age, performance score, 
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primary cancer and numbers of brain metastases. Compared to the previous study, we have a higher 
number of patients, indicating the need for further verification in future studies in larger cohorts. 
Figure 2. (a) Principal component analysis (PCA) score plot of PC-1 (explained variance 
71%) and PC-3 (explained variance 4%) based on single-pulse spectra (n = 39) showing 
the distribution of the metastases from four different primary cancer diagnoses; lung (blue), 
breast (red), colorectal (green) and melanoma carcinomas (yellow). The light blue colored 
part of the circles reflects the content of necrotic tissue determined by HES staining post 
HR-MAS; (b) Loading plots for PC-1 and PC-3; Samples with high score values for PC-1 
have higher lipid levels. High score values for PC-3 are mainly due to high levels of  
phosphocholine (PCho). 
 
2.2.2. Nile Red Analysis of Lipid Droplets 
MR visible lipids in brain metastases were further investigated by Nile Red staining to explore the 
origin of the lipid signals seen in the MR spectra. Nile Red is a selective stain for cytoplasmic lipid 
droplets and helps to study lipid droplet formation in pathological states [32]. The metastatic lung 
(a) 
(b) 
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carcinomas samples were used as representative samples for this experiment due to their 
heterogeneous nature as observed in the PCA score plot with a wide variation in lipid levels (Figure 2). 
Analysis of the fluorescent microscopy images from Nile Red stained samples showed a varying 
amount and size of lipid droplets (LD). Figure 3 demonstrates Nile Red fluorescent-stained images of 
LD in sections of three samples with different metabolic patterns. LD were observed in focal necrotic 
parts of the sample sections, whereas tumor cells, stroma and brain cells were devoid of lipid droplets. 
A significant correlation between microscopically visible lipid droplets estimated by Nile Red staining 
and MR visible lipid signals (1.3 ppm) was observed in the metastatic lung carcinomas (p = 0.01). This 
is not previously shown for brain metastases, but is in consistence with previous findings in brain 
tumors [25,29]. Distributions of lipid droplet size and number are shown in Figure 4. Smaller lipid 
droplets are distributed equally among samples with low, medium and high necrosis, while larger lipid 
droplets only are present in samples with high necrotic fraction.  
Figure 3. Nile Red fluorescent-stained images showing lipid droplets in three brain 
metastases originating from lung carcinoma (A, B, C) and their corresponding mean 
normalized single-pulse spectra (1.6–0.8 ppm), which demonstrate signal differences due 
to methylene (1.3 ppm) and methyl groups (0.9 ppm) in the mobile fatty acyl chains. 
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Figure 4. Distribution of lipid droplets for droplet area between 0 and 1.005 µm2 in bins of 
0.015 µm2. The x-axis represents droplet area distribution and the y-axis—droplet density 
(number LD/mm2). The red, purple and blue bars represent the mean number of LD in high 
(>70%) medium (40%–70%) and low (<40%) necrosis, respectively. 
 
2.2.3. Brain Metastases and Low-Molecular-Weight Metabolites 
The PCA score plot of the single-pulse spectra (Figure 2) shows mainly an association between 
lipid levels and necrotic tissue, but also an inverse association to the level of PCho, lactate (Lac) 
taurine (Tau), glycerophosphocholine (GPC) and creatine (Cr) among brain metastasis of different 
origin. Tumors with a lower fraction of necrosis (Figure 2b), irrespective of metastatic origin, showed 
relatively higher levels of small molecular metabolites and lower levels of Lac and lipids, probably due 
to the dilution of metabolites in necrotic tumors [33].  
In order to exclude the contributions from necrosis related metabolites and to evaluate the small 
molecular metabolites in detail, samples with low necrosis (<50%) were further explored using the 
macromolecule suppressed spin-echo spectra. PCA was performed using the region between  
4.68 and 2.98 ppm to exclude remnant lipid signals. The resulting score plot of PC-1 and PC-2  
(Figure 5a) and the corresponding loading plot (Figure 5b) indicated a higher amount of GPC in 
malignant melanoma metastases than those from colorectal and lung carcinomas. Elevated GPC levels 
may reflect alteration in the enzymatic activities that govern choline synthesis, degradation, 
phosphorylation and transport. Metastases from colon and lung carcinomas have similar metabolic 
signatures, and they cluster together in the lower half of the PCA score plot (Figure 5a), with relatively 
higher levels of Cr, Gly, Lac and Tau compared to melanomas. Metastases from lung carcinomas are 
more heterogeneous compared to those from colon carcinomas and have wide variations in PCho 
content and are distributed along PC-1 (Figure 5a). Previous HR-MAS studies comparing primary lung 
carcinomas and normal lung tissue showed an increased amount of Lac, PCho and GPC in the former, 
while primary colon carcinomas showed a higher content of Tau, PCho, Gly and Lac compared to 
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normal colon tissue [10,34]. Some of these metabolites, which distinguish primary lung and colorectal 
cancers from healthy tissues, overlap with the metabolites we identified in our analysis. To gain 
knowledge about the role of these metabolites in cancer dissemination, comparative metabolomic 
studies, including both primary and metastatic tissue, are necessary.  
Figure 5. (a) PCA score plot showing PC-1 (42%) and PC-2 (15%) of cpmgpr spectra 
(ppm region 4.68–2.98) from brain metastases with less than 50% necrotic tissue (n = 26); 
(b) The loading plot of PC-2 indicates the metabolites GPC, Cr, Tau, Gly, Cho and Lac as 
important signals that divide the subtypes. The positive dominating signal in the loading 
plot for PC-1 (not shown) was PCho, explaining the dispersion in PC-1 direction in  
the score plot. 
 
 
(a) 
(b) 
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3. Experimental Section 
The study protocol was approved by the Norwegian Social Science Data Services and the Regional 
Committee for Medical and Health Research Ethics. Written informed consent was obtained from all 
patients included. 
3.1. Patient and Sample Characterization  
Forty-nine patients with brain metastases (mean age 63, range: 38–81 years) scheduled for surgical 
resection of their metastases were enrolled to the study. Prior to surgery, the gross functional status of 
the patient was evaluated using KPS. All operations were performed under general anesthesia using 
the Sonowand neuronavigation system [35]. During surgery, most of the resected tissue was sent for 
routine histological analysis, while a small part of the fresh tissue was within two minutes (median time) 
snap-frozen in liquid nitrogen at −196 °C and stored in cryogenic vials. To prevent biochemical and 
structural degradation, the biopsy specimens were stored in liquid nitrogen until analysis by HR-MAS 
MRS. More details on the patients’ characteristics are shown in Table 1. 
3.2. Sample Preparation and HR-MAS Experiments 
The sample preparation was performed on an ice block to avoid degradation. Each sample was cut 
to fit a leak-proof insert (30 µL, Bruker: Kel-F) used in a zirconium HR-MAS rotor (4 mm). The insert 
was filled with 3 µL cold (about 4 °C) phosphate buffered saline based on deuterium oxide containing 
4.5 mM TSP (trimethylsilyl-tetradeuteropropionic acid) and 20 mM sodium formate (CHNaO2). Mean 
sample weight was 9.1 ± 4.8 mg. 
HR-MAS spectra were recorded at 4 °C using a 600 MHz spectrometer with a 1H/13C HR-MAS 
probe (Bruker Avance DRX600, Germany) spinning the samples at a rate of 5 kHz. A single-pulse 
sequence (Bruker: zgpr) and a water and lipid suppressing spin-echo Carr-Purcell-Meiboom-Gill 
sequence (Bruker: cpmgpr) were acquired and processed, as described elsewhere [16]. The spectral 
region between 4.6 and 0.5 ppm was used for chemometric analyses. Spectral assignments were 
performed based on previous HR-MAS MRS studies of brain tumors and metastases [16,36–38]. 
3.3. Histopathological Examination 
The surgical specimens of the brain metastases were embedded in paraffin wax and cut in several 
sections (5 µm thick) before staining with hematoxylin, eosin and saffron (HES-staining) for the 
routine histological analysis. After HR-MAS analyses, the samples were immediately transferred to 
formalin for subsequent histopathological examination and were processed similarly. In the HES 
sections, the fraction of tumor tissue, necrosis, fibrosis and gliosis were assessed by a neuropathologist 
(SHT) (Table 1). The samples were divided in to three groups, high (>70%) medium (40%–70%) and 
low (<40%) necrosis, based on their necrotic content. 
Nile Red staining was performed on a sub-cohort to further investigate the origin of the lipid signals 
seen in the MR spectra of brain metastases from lung carcinomas, and these samples were snap-frozen 
after HR MAS before being analyzed by Nile Red staining [32]. The metastatic lung carcinomas 
samples were used as representative samples for this experiment due to their expression in the PCA 
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score plot. A fluorescence microscope (Nikon eclipse 90i) with an Exciter S 572filter and a camera 
were used to observe and photograph the Nile Red stained lipid droplets, as they appeared red 
luminous in the tissue. The field of view was kept at the region where the maximum numbers of lipid 
droplets where observed in the sample under an objective of 60x magnification. The processing and 
analysis of the Nile Red fluorescence images were performed using ImageJ software (Version 1.42q, 
National Institutes of Health, Bethesda, MD). After converting color images to 8-bit gray scale, the 
background fluorescence was removed with the provided ‘Subtract background’ (rolling ball,  
radius = 50 pixels) option in Image J, and the lipid droplets were segmented by applying a manual 
threshold. The number and area of lipid droplets were calculated by “Analyze Particles”.  
3.4. MR Metabolomics 
All spectra were peak aligned by the warping algorithm icoshift [39] in MatLab (version 7.9.0; The 
Math Works, Natick, MA, USA) and baseline offset was corrected. The spectral regions between  
4.60–0.05 ppm and 4.68–0.05 ppm from pulse-acquired and spin echo spectra, respectively, were used 
as input for multivariate analyses. The spectral regions 3.69–3.62 ppm and 1.22–1.13 ppm were 
removed due to ethanol contamination. In order to eliminate the effect of differences in sample 
weights, the selected regions of the spectra were normalized by dividing each row of the data matrix 
by its average (mean normalization in Unscrambler (CAMO, version 10, Norway)).  
Principal component analyses (PCA) of mean-centered data were performed to explore the variation 
in the spectral data. PCA reduces the dimensionality of the data and summarizes the similarities and 
differences between multiple MR spectra using score plots. New variables, which are linear 
combinations of the original spectra carrying the greatest variance within the data called principle 
components (PCs), are created. The first PCs will be in the direction of maximum variance in the data 
set, and samples with similar metabolic profiles will appear close to each other in the score plots of 
PCs. The variables or metabolites, which are responsible for the grouping of samples in the score plots, 
are identified by the corresponding loading plots of the PCs. 
Partial least square discriminant analysis (PLS-DA) with cross validation was performed to 
investigate the relationship between the metabolic profiles (x) and clinical parameters (y). PLS models 
use both the x- and y-matrices simultaneously to find the latent variables (LVs) in x that best predict 
the y. PLS-DA attempts to discriminate between distinct classes and explains maximum separation 
between defined class samples in the data (x) [40]. To achieve a representative test and training set for 
the PLS-DA modeling, the sample selection algorithm Duplex was used [41]. The obtained test 
samples (n = 9) were kept out, while the training (n = 30) set was used to build the model. Both PCA 
and PLS-DA were performed using Unscrambler (CAMO, version 10, Norway). In order to evaluate 
whether sample classification was significantly better than random classification in two arbitrary 
groups, a permutation test was performed with 1000 permutations [42].  
To study associations between lipid signals, PCA score values and necrosis, statistical analyses 
were done using IBM SPSS Statistics 19 (New York, NY, USA). All statistical tests used were  
non-parametric, two-sided, where p-values below 0.05 were considered as statistical significant.  
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4. Conclusions  
In this study, we explored the metabolic profiles of metastatic brain tumors of different origin. 
Malignant melanomas were metabolically distinct, with a higher amount of GPC, while other subtypes 
were metabolically more heterogeneous. A significant correlation between lipids and necrosis in the 
metastatic tumors were observed. The study also confirms the cytoplasmic origin of MR visible lipid 
signals in metastases. However, there were no significant correlations between metabolic profiles and 
patient age or survival. MR spectroscopy is a useful tool for exploring the metabolic profiles of 
metastatic brain tumors, and future comparative metabolomic studies involving both primary and 
metastatic tissue may shed light on the role of metabolites in cancer dissemination.  
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